About pertuzuma b
HER2-targeted monoclonal antibody
Used for
- HER2-positive breast cancer, with other cancer medicines.
Usual adult dose
840 mg intravenously initially, then 420 mg every 3 weeks; dosing varies with treatment regimen.
Common side effects
- Diarrhea
- Nausea
- Hair loss
- Low white blood cell counts
Important warnings
- May cause serious heart problems; heart function is monitored.
- Can cause severe infusion reactions or allergic reactions.
- May cause serious harm to an unborn baby.
- Treatment requires confirmation of HER2-positive cancer.
Pregnancy
Can harm an unborn baby. Pregnancy testing and effective contraception during treatment and for 7 months after the last dose are recommended.
Breastfeeding
Breastfeeding is not recommended during treatment and for 7 months after the last dose.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.